Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, scheduled for June 30, 2025, will feature a presentation by CEO and Chairman Robert Bitterman, who will provide an update on the company's proprietary INTASYL® siRNA technology. The presentation will include progress reports on the ongoing clinical trial of the lead compound PH-762, which is being developed for the treatment of skin cancers. Positive interim safety and efficacy results have already been reported from the Phase 1b dose escalation clinical trial of PH-762. The presentation and live Q&A session can be accessed via the Renmark Financial Communications Inc. website, with a replay available post-event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.